Fast antimicrobial ASTar offers rapid antimicrobial susceptibility testing from positive blood cultures, delivering results in about six hours and significantly faster than competing diagnostics. This creates a compelling case for hospital labs aiming to shorten time-to-therapy and reduce broad-spectrum antibiotic use.

FDA CE readiness ASTar is CE-IVD certified and US-FDA cleared, signaling strong regulatory readiness and ease of market adoption across major regions. This reduces sales friction and supports enterprise-level procurement conversations with hospitals and lab networks.

Clinical impact The solution directly targets infectious disease diagnostics with a focus on sustainable healthcare outcomes, offering physicians quicker, data-driven decisions and potential improvements in patient outcomes and hospital stay costs.

SMB to midmarket fit With a headcount in the 51-200 range and revenues in the low single digits to mid millions, Q-linea sits in a space where mid-sized hospitals and regional lab networks could be primary customers, suggesting a sales strategy oriented toward group purchasing organizations and multi-site deployments.

Strategic partnerships Potential partners include large diagnostics players and service integrators who value rapid AST capabilities; collaborations could expand distribution, access to customer bases, and accelerate adoption in labs currently using slower or less precise methods.